Research programme: cardiovascular diagnostic imaging - EPIX Pharmaceuticals

Drug Profile

Research programme: cardiovascular diagnostic imaging - EPIX Pharmaceuticals

Alternative Names: EP-3533; EP-3600

Latest Information Update: 06 May 2010

Price : $50

At a glance

  • Originator EPIX Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 05 May 2010 Intellectual properties pertaining to EP 3600 are being auctioned in the US (http://www.finnwarnkegayton.com)
  • 06 Feb 2007 Preclinical trials in Magnetic resonance imaging in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top